The short version
- Why people research itAn ER-alpha-selective estrogen receptor modulator, studied in cells and rats for mammary antiproliferative activity and for the bone-agonist, reproductive-tissue-antagonist profile that defines the SERM class.
- What the evidence isNo human study of Y-134 exists — no trial, no case series, no pharmacokinetics in any species.
- What to watchA swollen painful calf or sudden breathlessness while using Y-134.
How Y-134 works
A raloxifene-derived benzothiophene that blocks the estrogen receptor rather than lowering estrogen — it is not an aromatase inhibitor. Y-134 keeps raloxifene's 6-hydroxy-2-(4-hydroxyphenyl)benzothiophene core and swaps raloxifene's piperidine side chain for an isopropyl-piperazine; that side chain is what the series was built around, and the series was reported as high-affinity ER-alpha-selective ligands. In CV-1 cells cotransfected with ER-alpha or ER-beta plus an estrogen-response-element luciferase reporter, Y-134 antagonized with an estimated IC50 of 0.52 nM at ER-alpha and 2.94 nM at ER-beta. Like its parent it is tissue-selective rather than uniformly blocking: antagonist in reproductive tissue, while the piperazine benzothiophene series it comes from was reported as potent agonists in bone. With comparable uterine suppression. It also activates the aryl hydrocarbon receptor.
Settle the class before the mechanism, because the wrong class is the expensive mistake here. Y-134 is a selective estrogen receptor modulator.
The structure tells you where it came from. Y-134 is [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]methanone, C28H28N2O3S, CAS 849662-80-2. That first half is raloxifene's own core: a benzothiophene bearing two phenolic hydroxyls, one at the 6-position and one on the 2-aryl ring.
- Topical
On the goal map: Aromatase & estrogen management (Testosterone & the male hormonal axis)
Research on Y-1348 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Theoretical — cells and rats only. ER-alpha-selective SERM characterized in a 2007 British Journal of Pharmacology paper; no human study of Y-134 exists, and no pharmacokinetics in any species.
Human clinical evidence
No human study of Y-134 exists — no trial, no case series, no pharmacokinetics in any species. The compound has been in the literature since 2005 as a chemical entity and since 2007 as a characterized SERM, and in roughly two decades nobody has published a human exposure to it.
No completed human trialA transdermal SERM has been tried in humans, with a different molecule, and the trial did not meet its endpoint. The gel did what a topical route is supposed to do — systemic endoxifen was minimal, median 0.3 ng/g against 13.0 ng/g for oral — and antiproliferative noninferiority of the gel was not confirmed, which the authors attribute to exactly that exposure difference. That is a different molecule and a breast application rather than general transdermal use, so it is not a result about Y-134. It is the closest human evidence anywhere near the route this product uses, and its direction is that low systemic exposure came at the cost of the biological effect.
Correlative data
Nothing. There is no human observational, association or uncontrolled data on Y-134 either. This tier is empty rather than thin, and saying so is more useful than filling it with raloxifene's epidemiology, which belongs to a different molecule that has been through phase 3 and has a label.
How the mechanism reads
Potent ER antagonism with a measured selectivity ratio. In CV-1 cells cotransfected with ER-alpha or ER-beta and an estrogen-response-element-driven luciferase reporter, the estimated IC50 was 0.52 nM at ER-alpha and 2.94 nM at ER-beta, which the authors call comparable to raloxifene. Five analogs from two structural series were evaluated and all bound ER-alpha more tightly than ER-beta.
MechanisticThe mammary-selectivity claim, which is the reason the compound has a name. Y-134 was more effective than raloxifene at arresting estrogen-induced outgrowth of mammary terminal end buds and mammary gland DNA synthesis, while the two drugs' inhibitory effects on the uterus were comparable. Better selectivity meant more mammary effect at equal uterine effect — not less uterine effect. Y-134 also suppressed estrogen-stimulated proliferation of ER-positive MCF-7 and T47D human breast cancer cells, with little cytotoxicity below 10 microM.
Experimental, animal or cellBone agonism belongs to the series, not yet to this molecule. The 2005 synthesis paper describing the piperazine-side-chain benzothiophenes reports them as high-affinity, ER-alpha-selective and potent agonists in bone tissue. That abstract does not name Y-134. The 2007 pharmacology paper that does name Y-134 measured uterus and mammary gland, not bone. So the bone half of the SERM profile is a property of the chemical family that nobody has published for this member.
MechanisticA second receptor, and it is not an estrogen receptor. Y-134 was identified in a structure-activity screen of seven raloxifene analogs as an aryl hydrocarbon receptor (AhR) activator: it induced AhR-mediated transcriptional activity and apoptosis in MDA-MB-231 triple-negative (ER-negative) human breast cancer cells, and suppressing AhR expression strongly reduced that apoptosis — so the effect required AhR. It also induced apoptosis in hepatoma cells without affecting cell cycle regulation. In the same paper, zebrafish embryo toxicity testing found Y-134 had a significantly better safety profile than raloxifene. That is the only comparative toxicity datum that exists for this molecule, and it is in fish embryos.
Experimental, animal or cellIndependent use as a tool compound corroborates the ER-alpha selectivity. An unrelated group studying estrogen and dopamine neuron firing used Y134 in rats as 'a selective ERalpha antagonist' alongside raloxifene, and pretreatment with either largely attenuated cocaine-inhibited firing of ventral tegmental area dopamine neurons. Independent researchers reaching for it as a selective ER-alpha antagonist is weak evidence about efficacy and reasonable evidence that the selectivity claim survived outside the originating lab.
Experimental, animal or cell
Sources
- Ning M, Zhou C, Weng J, Zhang S, Chen D, Yang C, Wang H, Ren J, Zhou L, Jin C, Wang MW. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). British Journal of Pharmacology 2007;150(1):19-28 · PMID 17115070
- Jang HS, Pearce M, O'Donnell EF, Nguyen BD, Truong L, Mueller MJ, Bisson WH, Kerkvliet NI, Tanguay RL, Kolluri SK. Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells. Biology (Basel) 2017;6(4):41 · PMID 29194351
- Zhang D, Yang S, Yang C, Jin G, Zhen X. Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine. Psychopharmacology (Berlin) 2008;199(4):625-35 · PMID 18516717
- Yang C, Xu G, Li J, Wu X, Liu B, Yan X, Wang M, Xie Y. Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo. Bioorganic & Medicinal Chemistry Letters 2005;15(5):1505-7 · PMID 15713417
- Khan SA, Mi X, Xu Y, Blanco LZ Jr, Akasha AM, Pilewskie M, Degnim AC, AlHilli Z, Amin AL, Hwang ES, Guenther JM, Kocherginsky M, Benante K, Zhang S, Helland T, Hustad SS, Gursel DB, Mellgren G, Dimond E, Perloff M, Heckman-Stoddard BM, Lee O. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial. JAMA Surgery 2023 (published online 23 October 2023) · PMID 37870954
Y-134 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy or breastfeeding: an estrogen-receptor blocker has no human safety data.
- Past clot in leg or lung: SERMs raise clot risk through liver proteins.
- Estrogen-sensitive cancer you are being treated for: no human study of Y-134 exists.
- Unexplained vaginal bleeding.
- Expecting pharmacokinetic knowledge: none exists in any species.
What’s expected
- No human effects are known; cells and rats are all there is.
- If it reaches the bloodstream: higher LH and testosterone in men from lost pituitary estrogen feedback.
- Skin irritation where it is applied.
Watch for
- A swollen painful calf or sudden breathlessness while using Y-134.
- Breast tenderness or swelling in a man.
- Hot flashes that appear.
- Spotting or abnormal bleeding.
Labs that tell you it’s working
- Estradiol, Sensitive [LC/MS-MS]
- LH & FSH
- Total Testosterone
- Lipid Panel
Y-134 is a raloxifene-derived, ER-alpha-selective SERM, not an aromatase inhibitor; with no human data, systemic leakage is the unknown.
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “Low T? Rule Out the Reversible Causes First” panel, explained
Y-134 FAQ4 common questions
- Is Y-134 approved for human use?
- No. Y-134 is a research compound. No completed randomized human trial has given it yet.
- What is Y-134 researched for?
- An ER-alpha-selective estrogen receptor modulator, studied in cells and rats for mammary antiproliferative activity and for the bone-agonist, reproductive-tissue-antagonist profile that defines the SERM class.
- Which labs show whether it's doing anything?
- Estradiol, Sensitive [LC/MS-MS]; LH & FSH; Total Testosterone; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Y-134: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



